GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
QUESTOR PHARMACEUTCL (QCOR) [hlAlert]

Rating:
Buy QCOR
up 1,191.03 %

QUESTOR PHARMACEUTCL (QCOR) rated Buy with price target $37 by Maxim Group

Posted on: Thursday,  Aug 25, 2011  9:25 AM ET by Maxim Group

Maxim Group rated Buy QUESTOR PHARMACEUTCL (NASDAQ: QCOR) on 08/25/2011. Previously Maxim Group rated Buy QUESTOR PHARMACEUTCL (NASDAQ: QCOR) on 02/19/2009.,
when the stock price was $7.25. Since then, QUESTOR PHARMACEUTCL has gained 1191.03% as of 08/14/2014's recent price of $93.60.
If you would have followed the previous Maxim Group's recommendation on QCOR, you would have gained 1191.03% of your investment in 2002 days.

Questcor Pharmaceuticals, Inc. (Questcor) markets H.P. Acthar Gel (repository corticotropin injection), an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis (MS), and the treatment of nephrotic syndrome. H.P. Acthar Gel (Acthar) is not indicated for, but is also used in treating patients with infantile spasms (IS). The Company also markets Doral (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. As of December 31, 2008, Acthar was approved in the United States for the treatment of exacerbations associated with MS, nephrotic syndrome and many other conditions with an inflammatory component.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/25/2011 9:25 AM Buy
None
27.54 37.00
as of 12/30/2011
1 Week down  -2.85 %
1 Month down  -7.49 %
3 Months up  52.53 %
1 YTD up  182.28 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/27/2011 9:25 AM Buy
None
30.06 32.00
5/13/2011 8:25 AM Buy
None
23.09 28.00
4/7/2011 9:25 AM Buy
None
18.67 24.00
5/11/2010 11:25 AM Buy
None
8.83 13.00
2/19/2009 8:25 AM Buy
None
7.25 11.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy